Skip to main content
. 2019 Nov 1;18(1):57–68. doi: 10.1007/s40258-019-00528-w

Table 2.

Base-case analysis

Screening strategy Cost, R$ Incr. cost, R$ QALY Incr. QALY ICER (R$/QALY gained)
Opportunistic ophthalmology referral-based 841 0 10.136 0 0
Systematic teleophthalmology-based 1744 903 10.178 0.042 21445
Systematic ophthalmology referral-based 1748 4 10.165 − 0.012 Dominated

C/E cost-effectiveness ratio, ICER incremental cost-effectiveness ratio, Incr. incremental, (Incr. cost/Incr. QALY), QALY quality-adjusted life-year, R$ Reais